|
| Pathway ID | Pathway name | Molecule |
|
| 200071 | Regulation of CDC42 activity | BCAR3 |
| hsa04260 | Cardiac muscle contraction | CACNG6 |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | CACNG6 |
| hsa05410 | Hypertrophic cardiomyopathy (HCM) | CACNG6 |
| hsa05414 | Dilated cardiomyopathy | CACNG6 |
| hsa04010 | MAPK signaling pathway | CACNG6 |
| 194002 | Glucocorticoid biosynthesis | CYP21A2 |
| 193993 | Mineralocorticoid biosynthesis | CYP21A2 |
| 211976 | Endogenous sterols | CYP21A2 |
| 209943 | Steroid hormones | CYP21A2 |
| 196071 | Metabolism of steroid hormones and vitamins A and D | CYP21A2 |
| 211897 | Cytochrome P450, arranged by substrate type | CYP21A2 |
| 211945 | Phase 1, functionalization of compounds | CYP21A2 |
| 211859 | Biological oxidations | CYP21A2 |
| hsa00140 | Steroid hormone biosynthesis | CYP21A2 |
| 556833 | Metabolism of lipids and lipoproteins | CYP21A2 |
| 1430728 | Metabolism | CYP21A2 |
| 1462054 | Alpha-defensins | DEFA3 |
| 1461973 | Defensins | DEFA3 |
| hsa05202 | Transcriptional misregulation in cancer | DEFA3 |
| 168249 | Innate immune system | DEFA3 |
| 168256 | Immune system | DEFA3 |
| 114508 | Effects of PIP2 hydrolysis | DGKD |
| hsa00561 | Glycerolipid metabolism | DGKD |
| hsa04070 | Phosphatidylinositol signaling system | DGKD |
| hsa00564 | Glycerophospholipid metabolism | DGKD |
| 416476 | G alpha (q) signalling events | DGKD |
| 388396 | GPCR downstream signaling | DGKD |
| 372790 | Signaling by GPCR | DGKD |
| 162582 | Signal transduction | DGKD |
| 76002 | Platelet activation, signaling, and aggregation | DGKD; LEFTY2 |
| 109582 | Hemostasis | DGKD; LEFTY2 |
| 1433617 | Regulation of signaling by NODAL | LEFTY2 |
| 1181150 | Signaling by NODAL | LEFTY2 |
| 114608 | Platelet degranulation | LEFTY2 |
| 76005 | Response to elevated platelet cytosolic Ca2+ | LEFTY2 |
| hsa04350 | TGF-beta signaling pathway | LEFTY2 |
| 1266738 | Developmental biology | LEFTY2 |
|
